These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 7528030)

  • 21. Recombinant leukocyte A interferon with doxorubicin. A phase I study in advanced solid neoplasms and implications for hepatocellular carcinoma.
    Creagan ET; Long HJ; Frytak S; Moertel CG
    Cancer; 1988 Jan; 61(1):19-22. PubMed ID: 2825959
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Hepatocellular carcinoma with cirrhosis: treatment with doxorubicin. Phase II evaluation].
    Barbare JC; Ballet F; Petit J; Poupon R; Darnis F
    Bull Cancer; 1984; 71(5):442-5. PubMed ID: 6084528
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neoadjuvant chemotherapy and liver transplantation for hepatocellular carcinoma: a pilot study in 20 patients.
    Stone MJ; Klintmalm GB; Polter D; Husberg BS; Mennel RG; Ramsay MA; Flemens ER; Goldstein RM
    Gastroenterology; 1993 Jan; 104(1):196-202. PubMed ID: 8380393
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Daily alternating administration of high-dose alpha-2b-interferon and interleukin-2 bolus infusion in metastatic renal cell cancer. A phase II study.
    Bergmann L; Fenchel K; Weidmann E; Enzinger HM; Jahn B; Jonas D; Mitrou PS
    Cancer; 1993 Sep; 72(5):1733-42. PubMed ID: 8348502
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combined regimen of cisplatin, doxorubicin, and alpha-2b interferon in the treatment of advanced malignant pleural mesothelioma: a Phase II multicenter trial of the Italian Group on Rare Tumors (GITR) and the Italian Lung Cancer Task Force (FONICAP).
    Parra HS; Tixi L; Latteri F; Bretti S; Alloisio M; Gravina A; Lionetto R; Bruzzi P; Dani C; Rosso R; Cosso M; Balzarini L; Santoro A; Ardizzoni A
    Cancer; 2001 Aug; 92(3):650-6. PubMed ID: 11505411
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Similar effects of recombinant interferon-alpha-2b and natural interferon-alpha when combined with intra-arterial 5-fluorouracil for the treatment of advanced hepatocellular carcinoma.
    Uka K; Aikata H; Takaki S; Miki D; Jeong SC; Hiramatsu A; Kodama H; Shirakawa H; Kawakami Y; Takahashi S; Toyota N; Ito K; Chayama K
    Liver Int; 2007 Nov; 27(9):1209-16. PubMed ID: 17919232
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A phase II trial of interferon alpha-2A, 5-fluorouracil, and cisplatin in patients with advanced esophageal carcinoma.
    Ilson DH; Sirott M; Saltz L; Heelan R; Huang Y; Keresztes R; Kelsen DP
    Cancer; 1995 May; 75(9):2197-202. PubMed ID: 7712428
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I evaluation of radiation combined with recombinant interferon alpha-2a and BCNU for patients with high-grade glioma.
    Rajkumar SV; Buckner JC; Schomberg PJ; Cascino TL; Burch PA; Dinapoli RP
    Int J Radiat Oncol Biol Phys; 1998 Jan; 40(2):297-302. PubMed ID: 9457812
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma.
    Leung TW; Patt YZ; Lau WY; Ho SK; Yu SC; Chan AT; Mok TS; Yeo W; Liew CT; Leung NW; Tang AM; Johnson PJ
    Clin Cancer Res; 1999 Jul; 5(7):1676-81. PubMed ID: 10430068
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combination therapy with transarterial chemoembolization and interferon-alpha compared with transarterial chemoembolization alone for hepatitis B virus related unresectable hepatocellular carcinoma.
    Li M; Lu C; Cheng J; Zhang J; Cao C; Xu J; Xu J; Pan H; Zhong B; Tucker S; Wang D
    J Gastroenterol Hepatol; 2009 Aug; 24(8):1437-44. PubMed ID: 19486255
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recombinant interferon alfa 2b therapy in a patient with metastatic hepatocellular carcinoma.
    Yuen MF; Hon C; Hui CK; Siu CW; Lai CL
    J Clin Gastroenterol; 2002 Sep; 35(3):272-5. PubMed ID: 12192207
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaires 86 Trial.
    Solal-Céligny P; Lepage E; Brousse N; Tendler CL; Brice P; Haïoun C; Gabarre J; Pignon B; Tertian G; Bouabdallah R; Rossi JF; Doyen C; Coiffier B
    J Clin Oncol; 1998 Jul; 16(7):2332-8. PubMed ID: 9667247
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Complete remission induction with combined VBMCP chemotherapy and interferon (rIFN alpha 2b) in patients with multiple myeloma.
    Oken MM; Kyle RA; Greipp PR; Kay NE; Tsiatis A; Gregory SA; Spiegel R J; O'Connell M J
    Leuk Lymphoma; 1996 Feb; 20(5-6):447-52. PubMed ID: 8833401
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A phase I trial of interferon alpha-2b with folinic acid and 5-fluorouracil administered by 4-hour infusion in metastatic colorectal carcinoma.
    Kreuser ED; Hilgenfeld RU; Matthias M; Hoksch B; Boewer C; Oldenkott B; Knauf WU; Boese-Landgraf J; Schalhorn A; Zeitz M
    Semin Oncol; 1992 Apr; 19(2 Suppl 3):197-203. PubMed ID: 1557647
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Survival results among patients with alpha-fetoprotein-positive, unresectable hepatocellular carcinoma: analysis of three sequential treatments of the RTOG and Johns Hopkins Oncology Center.
    Abrams RA; Pajak TF; Haulk TL; Flam M; Asbell SO
    Cancer J Sci Am; 1998; 4(3):178-84. PubMed ID: 9612600
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination PEG-IFN a-2b/ribavirin therapy following treatment of hepatitis C virus-associated hepatocellular carcinoma is capable of improving hepatic functional reserve and survival.
    Ishikawa T; Higuchi K; Kubota T; Seki K; Honma T; Yoshida T; Kamimura T
    Hepatogastroenterology; 2012; 59(114):529-32. PubMed ID: 22024226
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combined transcatheter arterial chemoembolization and local radiotherapy of unresectable hepatocellular carcinoma.
    Seong J; Keum KC; Han KH; Lee DY; Lee JT; Chon CY; Moon YM; Suh CO; Kim GE
    Int J Radiat Oncol Biol Phys; 1999 Jan; 43(2):393-7. PubMed ID: 10030267
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomised trial of vindesine plus interferon-alpha 2b compared with interferon-alpha 2b or vindesine alone in the treatment of advanced malignant melanoma.
    Vorobiof DA; Bezwoda WR
    Eur J Cancer; 1994; 30A(6):797-800. PubMed ID: 7917540
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recombinant a2 interferon (a-IFN) with chemo-hormonal therapy in patients with hepatocellular carcinoma (HCC).
    Kountouras J; Boura P; Karolides A; Zaharioudaki E; Tsapas G
    Hepatogastroenterology; 1995 Feb; 42(1):31-6. PubMed ID: 7782031
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bioembolisation for unresectable hepatocellular carcinoma: preliminary results of a translational research study.
    Goker E; Sanli UA; Yuzer Y; Uslu R; Karabulut B; Memis A; Coker A; Mentes A
    J Exp Clin Cancer Res; 2004 Sep; 23(3):403-9. PubMed ID: 15595628
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.